At the EAU25 Congress, Dr. Sarah Psutka MD MSc shared promising data from the SunRISe-4 trial evaluating neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible or cisplatin-refusing.
This novel combination therapy demonstrated encouraging results, with a pathological complete response rate (pCR) of 42% and an overall pathological response rate (pOR) of 62%, outperforming cetrelimab monotherapy (23% and 36%, respectively). Treatment-related adverse events were mostly low-grade urinary events.
Crucially, the combination did not lead to delays in planned radical cystectomy (RC). Among 76 patients who underwent RC, 84% received surgery within the protocol-defined window, with only one delay attributed to treatment.
These findings suggest that TAR-200 + cetrelimab may offer an effective neoadjuvant alternative without compromising health status or surgical timelines in cisplatin-ineligible patients. Further analyses on long-term outcomes, including metastasis and survival, are underway.
We thank Dr. Sarah Psutka and the entire SunRISe-4 study team for their valuable contributions to advancing care for patients with MIBC.
For more information, view the full presentation here: https://lnkd.in/dRMcRN9D
